PD Dr. med.
Aurelius Omlin
Onkozentrum Zürich

Please save the date to join us in Switzerland on Friday, March 6, 2026 for the hybrid ASCO Direct™ GU Highlights Meeting.
Requested CME: SGU | SSMO
Registration: https://events.springermedicine.com/asco-direct-gu-highlights-switzerland/
The ASCO Direct™ GU Highlights Meeting is an educational program containing selected original sessions from the 2026 ASCO Genitourinary Cancers Symposium on prostate, renal cell and urothelial cancer. You will have the opportunity to view the original sessions and discuss the clinical relevance and implications for Swiss treatment landscape of study outcomes with your colleagues.
We look forward to welcoming you at the ASCO Direct™ GU Highlights meeting 2026.
Your faculty
PD Dr. med. Aurelius Omlin and Prof. Dr. med. Arnoud Templeton
The ASCO Direct™ GU Highlights Meeting is an official ASCO Direct™ program and Springer Health+ is the official local partner for this event. Please feel free to contact asco@springer.com if you have any questions.
ASCO DIRECT™ programs are officially licensed by the American Society of Clinical Oncology, Inc. (ASCO). Each presentation is provided solely for educational and informational purposes and personal use only. No part of any presentation may be edited or altered, or reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, nor may it be used for commercial purposes, without in each case the express written permission of ASCO. The ideas and opinions expressed in this presentation do not necessarily reflect those of ASCO. The mention of any company, product, service, or therapy does not constitute an endorsement of any kind by ASCO. It is the responsibility of the treating physician or other health care provider, relying on independent experience and knowledge of the patient, to determine drug dosages and the best treatment for the patient. Viewers are advised to check the appropriate medical literature and the product information currently provided by the manufacturer of each drug to be administered to verify , among other matters, the dosage, the method and duration of administration, or contraindications. ASCO assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the material contained in this presentation or any errors or omissions. © 2025 American Society of Clinical Oncology, Inc. All rights reserved worldwide.
Gleisarena, Zollstrasse 17, 8005 Zürich
| 16:00 19:30 | The program will include educational sessions and will be available in February 2026 |
Onkozentrum Zürich
Claraspital Basel
Kantonsspital Graubünden
Luzerner Kantonsspital
Hirslanden Zürich
Inselspital Bern
Universitätsspital Basel
EOC Bellinzona